ClinicalTrials.gg
TerminatedNCT05631574Updated Feb 7, 2025

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

A Phase 1 interventional study of BMF-219 in Non Small Cell Lung Cancer, Pancreatic Cancer and Colorectal Cancer, sponsored by Biomea Fusion Inc.. Terminated at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Biomea Fusion Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
2,491st of 2,995
13 · median 56
Started
2023
with 163 others
Phase 1
927 of 3,368
134 open now
Registered
2,773rd of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 2,491st largest by enrollment of the 2,995 interventional ones that give a count, is one of 164 that started in 2023, is one of 927 in phase 1, and was the 2,773rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

Read the detailed description

This is a dose finding study to determine the safety and tolerability, pharmacokinetics and pharmacodynamics, and clinical activity of escalating doses of BMF-219 administered orally (PO) either once daily (QD) or twice daily (BID) in 28-day cycles. After observing acceptable safety performance in these dosing regimens, additional subjects will be enrolled to assess efficacy in the determination of the OBD for use as a RP2D.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • NSCLC
  • PDAC
  • CRC
  • Relapsed Cancer
  • Refractory Cancer
  • Stage III Pancreatic Cancer
  • Stage IV Pancreatic Cancer
  • Stage III Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer
  • Stage III Colorectal Cancer
  • Stage IV Colorectal Cancer
  • Stage III NSCLC
  • Stage IV NSCLC
  • KRAS Mutation-Related Tumors

Keywords

  • Oral Covalent Menin Inhibitor
  • Relapsed
  • Refractory
  • Irreversible Menin Inhibitor
  • Menin Inhibitor
  • Unresectable
  • Locally Advanced
  • Metastatic
  • Menin
  • Menin Therapy
  • KRAS
  • KRAS Mutated
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults with a confirmed diagnosis of unresectable, locally advanced and/or Stage IIIB/IV NSCLC, Stage III/IV PDAC and/or Stage III/IV CRC with no curative-intent treatment options and documented activating KRAS mutation (without known additional actionable driver mutations such as EGFR, ALK or ROS1)
  2. Documented progression and after ≥ 1 (≥ 2 and

    ≤ 4 prior lines for NSCLC) with adequate and resolution of treatment-related toxicities to ≤ Grade 2

  3. PS of 0-2 (0-1 for PDAC) and a > 3 months in the opinion of the Investigator
  4. Adequate hematological, liver, and renal function
  5. Men and women of must use adequate measures for the duration of the trial and at least 90 days after discontinuing study treatment

Exclusion criteria

Exclusion Criteria

  1. Symptomatic and/or untreated CNS or , pre-existing ILD or pericardial/pleural effusion of ≥ grade 2 or requiring chronic oxygen therapy for or pleural effusions
  2. Serious concomitant disorder including infection
  3. Known positive test for , , surface antigen
  4. Concurrent in the previous 2 years
  5. Prior menin inhibitor therapy
  6. Requiring treatment with a strong or moderate inhibitor/inducer
  7. Significant cardiovascular disease or or QTcB prolongation.
  8. Major surgery within 4 weeks prior to first dose
  9. Women who are pregnant or lactating.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Escalation Phase

    Dose Escalation Phase will group all disease indications (NSCLC, PDAC, and CRC) together to assess the safety of each dose level. Participants will receive escalating dose BMF-219 orally once per day or twice per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).

    Drug: BMF-219

  • Experimental
    Expansion Phase

    Dose Expansion Phase will enroll additional subjects independently in each disease indication: Cohort 1: Participants with NSCLC Cohort 2: Participants with PDAC Cohort 3: Patients with CRC Cohorts 1, 2, and 3 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug.

    Drug: BMF-219

Interventions

  • BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

06

What researchers measure

Primary outcomes

  1. To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.

    OBD/RP2D as determined by the number of subjects receiving BMF-219 monotherapy who experience Dose-Limiting Toxicities (DLTs) within each dose level. A DLT is defined as any clinically significant Adverse Event within 28 days of starting BMF-219 treatment and considered to be related to the IMP. Adverse Events will be assessed per CTCAE v5.0.

    Time frame: 30 months

  2. To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.

    OBD/RP2D as measured by objective response rate (ORR). ORR will be assessed using RECIST 1.1 per investigator assessment.

    Time frame: 30 months

Secondary outcomes

  1. To evaluate the safety and tolerability of BMF-219 monotherapy.

    Safety and tolerability will be determined using treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) as outcomes.

    Time frame: 46 months

  2. To evaluate the pharmacokinetics of BMF-219.

    Pharmacokinetics will be determined using maximum observed plasma concentration (Cmax ).

    Time frame: 46 months

  3. To evaluate the pharmacokinetics of BMF-219.

    Pharmacokinetics will be determined time to maximum plasma concentration (tmax).

    Time frame: 46 months

  4. To evaluate the pharmacokinetics of BMF-219.

    Pharmacokinetics will be determined using the AUC from time 0 to last quantifiable concentration (AUClast ).

    Time frame: 46 months

  5. To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.

    Efficacy will be determined using duration of response (DOR), defined by the duration of time from the date of initial response of PR or better to the date of disease progression or death due to any cause, whichever occurs first. DOR will be assessed using RECIST 1.1 per investigator assessment.

    Time frame: 46 months

  6. To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.

    Efficacy determined by disease control rate (DCR), defined as the proportion of response-evaluable subjects who maintain disease control (Complete Response, Partial Response or SD as per RECIST 1.1) from first dose through Week 6.

    Time frame: 46 months

07

Study locations

23 sites
  • Cancer Treatment Centers of America - Phoenix
    Goodyear, Arizona 85338, United States
  • California Cancer Associates for Research and Excellence (cCARE)
    Encinitas, California 92024, United States
  • University of California, San Diego
    La Jolla, California 92037, United States
  • Sarah Cannon Research Institute at HealthONE
    Denver, Colorado 80237, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Cancer Treatment Centers of America - Atlanta
    Atlanta, Georgia 30269, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern Univeristy
    Chicago, Illinois 60611, United States
  • Cancer Treatment Centers of America - Chicago
    Zion, Illinois 60099, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine - Siteman Cancer Center
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • NEXT Oncology
    San Antonio, Texas 78229, United States
  • NEXT Virginia
    Fairfax, Virginia 22031, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital Yonsei University Health System - PPDS
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Jan 2025, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Nov 30, 2022
StartActual
Jan 12, 2023
Primary completionActual
Jan 15, 2025
CompletionActual
Jan 15, 2025
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05631574
Lead sponsor
Biomea Fusion Inc.
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Jan 12, 2023
Primary completion
Jan 15, 2025
Completion
Jan 15, 2025
Last update
Feb 7, 2025

Study contacts

Steve Morris, MD
study director · Biomea Fusion Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icovamenib

Start the discussion